James Mohler, MD – Dr. Mohler is Associate Director and Senior Vice-President for Translational Research, Chief, Inter-Institutional Acaemics; Professor of Oncology; and Attending Surgeon, Department of Urology. He was recruited in 2003 after 16 years at the University of North Carolina at Chapel Hill (UNC) where he remains Adjunct Professor of Urology. Dr. Mohler’s clinical practice focuses upon prostate cancer and robot-assisted laparoscopic surgery. His laboratory focuses upon the role of the androgen receptor in racial differences in prostate cancer aggressiveness and prostate cancer recurrence during androgen deprivation therapy. He has authored or co-authored more than 200 publications and book chapters and a book “Androgen Action in Prostate Cancer.” He serves on the editorial boards of The Prostate, Journal of the National Comprehensive Cancer Network, and Therapeutic Advances in Urology, and reviews for several journals including Science, Journal of Clinical Oncology, Cancer, Cancer Research, Clinical Cancer Research, Journal of Urology and Urology.
Dr. Mohler introduces the clinical staff and scientists who make up the Urology Fellowship faculty at Roswell Park.
Khurshid Guru, MD – Dr. Guru joined the faculty at RPCI in 2005 after completing Fellowship in robot-assisted surgery at Henry Ford Hospital in Detroit, Michigan. At RPCI, he is Associate Professor of Oncology and Director of the Robotic Surgery Program. In partnership with Professor Kesavadas, he developed one of the first robotic surgical simulators for robotic assisted surgery. The simulator is used currently in 13 major academic centers including Cornell University, Cleveland Clinic and Henry Ford Health System. This work has resulted in several patents, which includes pioneering work in haptic enabled, augmented reality training.
Eric C. Kauffman, MD – Dr. Kauffman is Assistant Professor of Oncology in the Departments of Urology and Genetics at RPCI. He came to RPCI in 2012 from the National Cancer Institute, Bethesda, Maryland.
Qiang John Li, MD, PhD – Dr. Li is Assistant Professor of Oncology in the Department of Urology. He recently came to Roswell Park after completing a fellowship at Memorial Sloan Kettering Cancer Center in New York. He specializes in surgery for patients with genitourinary malignancy, including cancers of bladder, kidney, prostate and testis. His expertise includes open, endoscopic and minimally invasive techniques for the treatment of genitourinary cancers. The treatment of genitourinary cancer is complex and continues to evolve. It’s essential for patients to have a thorough knowledge and understanding of their options at the time of cancer diagnosis. The goal of our team is to provide appropriate curative therapeutic intervention and improve the quality of life of patients with genitourinary cancers. I work closely with colleagues in medical oncology, radiation oncology, and pathology to deliver the most up-to-date, multidisciplinary care which is tailored based on each patient’s circumstances.
Dr. Li’s clinical and translational research is to identify biomarkers of bladder cancer that are associated tumor behavior and responses to different therapies. This will help us individualize treatment for each patient based on his or her tumor’s features and disease status. For the patients, this could mean access to the most appropriate therapy or therapy combination.
Thomas Schwaab, MD, PhD – Dr. Schwaab is Associate Professor of Oncology in the Departments of Urology and Immunology at RPCI. He came to RPCI in 2009 from the Center for Urologic Care, Concord Hospital, Concord, NH. He also served as an Adjunct Assistant Professor of Medicine in the Immunologic Therapy Program, Norris Cotton Cancer Center, Dartmouth Medical School and an Adjunct Assistant Professor of Surgery at the Dartmouth Hitchcock Medical Center, Lebanon, NH. He provides laparoscopic and robot-assisted surgery to patients diagnosed with kidney cancer and other genitourinary cancers. His laboratory focuses upon novel immunotherapies for kidney and prostate cancers.
Willie Underwood III, MD, MPH, MSci – Dr. Underwood is Associate Professor, Department of Urology and Associate Professor, Office of Cancer Health Disparities Research at RPCI. He came to RPCI in 2008 from Wayne State University and Karmanos Cancer Institute, Detroit, MI, where he served as Assistant Professor in the Department of Urology. His research interests include prostate cancer treatment decision-making, prostate cancer survivorship and quality of life and understanding the role of cancer risk perception in cancer screening. His clinical practice focuses upon minimally invasive surgery for kidney, adrenal and prostate cancers.
Jason Muhitch, PhD – Dr. Muhitch is an Assistant Professor of Oncology in the Department of Urology. He came to RPCI in January 2014. Dr. Muhitch is establishing an independent research program in tumor immunology with a focus on mechanisms of vaccine enhancement.
Beth Pflug, PhD – Dr. Pflug is an Associate Professor of Oncology in the Department of Urology. She came to RPCI in March 2015. Dr. Pflug completed her postdoctoral training at Johns Hopkins University, Baltimore, MD in 2000 before joining the faculty in the Department of Urology at the University of Pittsburgh and then the Department of Medicine at Indiana University in 2009.
Gary Smith, PhD – Dr. Smith came to RPCI in 2006 from UNC, where he served as Professor in the Department of Pathology and Laboratory Medicine. Dr. Smith is a co-founder (with Dr. Mohler) of AndroBioSys, Inc., which is pioneering new human tissue-based models for drug testing and developing new treatments for prostate disease. His research interests include prostate cancer, stem cells, and endothelial cell biology.
Yue Wu, PhD - Dr. Wu's research interest is androgen metabolism and androgen receptor signaling in prostate cancer. Specifically, his research projects are focused on prostatic androgen trafficking and metabolism by prostatic epithelial cells and cancer cells, and how androgen metabolism affects biology and clinical characteristics of prostate cancer. The ultimate goal is to delineate mechanisms underlying the progression of prostate cancer to castration recurrent disease, and to identify novel modalities to prevent or treat castration recurrent prostate cancer.
Saby George, MD – Dr. George is Associate Professor of Oncology at Roswell Park. He came to RPCI from the University of Texas Health Sciences Center at San Antonio, San Antonio, TX. Dr. George’s kidney cancer research interests include novel drug development, mechanism of resistance formation to tyrosine kinase inhibitors and development of biomarkers. His prostate cancer research interests include castration-recurrent prostate cancer, improving androgen deprivation therapy and biomarker development.
Michael Kuettel, MD, PhD, MBA – Dr. Kuettel is Professor of Oncology and Chair, Department of Radiation Oncology at RPCI. He came to RPCI in 1999 from Georgetown University School of Medicine. His clinical practice is limited to urologic malignancies. He runs the bi-weekly Localized Prostate Cancer Conference that is attended by Fellows and urologists from RPCI and the greater Buffalo region. Fellows have frequent and regular interactions with Dr. Kuettel during the course of patient care.
Anurag Singh, MD – Dr. Singh is Associate Professor of Radiation Oncology and the Director of Clinical Radiation Research at RPCI. He came to RPCI in 2007 from the Radiation Oncology Branch of NCI where he was Attending Physician and Head of the Molecular Imaging Section. His research focuses on the use of magnetic resonance imagining (MRI) to diagnose and guide interventions for prostate cancer.
Gissou Azabdaftari, MD – Dr. Azabdaftari was appointed Assistant Professor of Oncology in the Department of Pathology and Laboratory Medicine at RPCI in March 2010 and Chief, Urologic Pathology, June 2013. She joined RPCI after four years on faculty at the University of Colorado, Denver, Health Sciences Center. She completed a GU pathology Fellowship with Mark Rubin, MD at Harvard. Her primary research interest is prostate cancer.
Craig Hendler, MD – Dr. Hendler is a staff physician in the Department of Diagnostic Radiology.
Wendy Huss, PhD – Assistant Member, Pharmacology & Therapeutics; Dr. Wendy Huss joined the Roswell Park Cancer Institute (RPCI) in 2005 as Assistant Professor in the Department of Urologic Oncology. In 2008 she joined the Department of Pharmacology & Therapeutics.Dr. Huss earned her doctoral degree in Molecular and Cellular Biology from Baylor College of Medicine, Houston, TX, in 2001 and completed a postdoctoral fellowship in the Department of Pathology and Laboratory Medicine from the University of North Carolina.Dr. Huss has demonstrated ABCG2-medicated efflux of androgen in putative prostate stem cells and her research interests include the role of androgen regulation or prostate stem cells and targeting the malignant prostate stem cell as a source of recurrent prostate cancer.Dr. Huss is a member of the American Association for Cancer Research, Society of Basic Urologic Research and Women in Cancer Research. She has authored or co-authored more than 30 articles and abstracts.